Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Xencor, Inc. (XNCR) PT Lowered to $31 at RBC Capital
June 14, 2024 6:25 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Xencor, Inc. (NASDAQ: XNCR) to $31.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "This morning XNCR disclosed the company has regained plamotamab (CD20 x CD3) as partner Janssen will terminate its... More
